We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Management of myelofibrosis and concomitant advanced cutaneous squamous cell carcinoma with ruxolitinib associated with cemiplimab.
- Authors
Di Prima, Alessio; Botticelli, Andrea; Scalzulli, Emilia; Colafigli, Gioia; Pepe, Sara; Lisi, Chiara; Marchetti, Paolo; Martelli, Maurizio; Foà, Robin; Breccia, Massimo
- Abstract
Dear Editor Ruxolitinib is an oral target small molecule inhibitor of Janus kinase (JAK) 1 and 2 approved for the treatment of myelofibrosis (MF) and polycythemia vera (PV) patients [[1]]. Long-term findings from the COMFORT-II study, a phase 3 trial of ruxolitinib versus best available therapy (BAT) for MF, have indicated an increased risk of newly diagnosed non-melanoma skin cancer (basal cell carcinoma [BCC] and squamous cell carcinoma [SCC]) in 17.1% of patient in the ruxolitinib arm and in only 2.7% of patients on the BAT arm [[3]]. Our elderly patient developed a SCC during treatment with ruxolitinib, but he had been treated earlier for several years with hydroxyurea: therefore, a iatrogenic pathogenesis cannot be excluded as the cause of the SCC [[4]].
- Subjects
SKIN cancer; RUXOLITINIB; SQUAMOUS cell carcinoma; MYELOFIBROSIS; CEMIPLIMAB
- Publication
Annals of Hematology, 2021, Vol 100, Issue 8, p2117
- ISSN
0939-5555
- Publication type
Letter
- DOI
10.1007/s00277-020-04236-7